Adaptive Biotechnologies Sees Its Cancer Test Featured in 89 Studies at Major Blood Disease Conference

Author: Benzinga Newsdesk | November 24, 2025 07:34am

Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in 89 abstracts, including 36 oral presentations, at the 67th Annual Meeting of the American Society of Hematology (ASH) taking place Dec. 6–9, 2025, in Orlando.

Key highlights include:

• Abstracts featuring clonoSEQ MRD data span multiple myeloma (MM), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and other blood cancers, underscoring its position as the most widely used and validated next-generation sequencing-based MRD test in lymphoid malignancies.
• More than 17 presentations demonstrate how clonoSEQ MRD assessment is informing patient treatment decisions in real world clinical practice, including studies to guide treatment in ALL, CLL, MM, MCL and DLBCL.
• Continued expansion of clonoSEQ use in clinical trials to enable the deepest assessment of treatment responses for novel regimens and across a wide range of therapeutic modalities, including CAR T, bispecific antibodies, and other targeted therapies.
  
  
  
   

"It's energizing to see the breadth of ASH presentations incorporating clonoSEQ this year, highlighting how integral MRD testing has become in patient care and clinical research across hematologic oncology," said Susan Bobulsky, chief commercial officer, MRD, Adaptive Biotechnologies. "This momentum reflects the multifaceted role MRD is playing in modern lymphoid cancer care—from guiding treatment decisions to accelerating therapeutic innovation."

Posted In: ADPT